source
- Pharma faces $500B risk as patents expire, with Merck most exposed by 2028More than $500 billion in global prescription sales could be threatened by generic competition between 2026 and 2032, according to Norstella data cited by Evaluate. Merck is the most immediately e…
- BMS reports phase 3 successes in IPF drug and neuroendocrine tumor radiotherapyBristol Myers Squibb announced that two of its phase 3 trials have met primary endpoints, marking important milestones as the company seeks growth beyond its patent expirations. The Aloft-IPF stud…